Literature DB >> 16784975

B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.

Vítor Trovisco1, Paula Soares, Manuel Sobrinho-Simões.   

Abstract

The very recent discovery of B-RAF point mutations as the most prevalent genetic alteration in papillary thyroid carcinoma has revolutionized the molecular knowledge of thyroid malignancies. In this review, we address the role played by such mutations in the etiopathogenesis, diagnosis, prognosis, and therapy selection of thyroid cancer, with an emphasis on papillary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784975     DOI: 10.1016/j.humpath.2006.03.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Authors:  Neslihan Kurtulmus; Mete Duren; Umit Ince; M Cengiz Yakicier; Onder Peker; Ozlem Aydın; Ender Altiok; Serdar Giray; Halil Azizlerli
Journal:  Endocrine       Date:  2012-03-17       Impact factor: 3.633

Review 2.  Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.

Authors:  Ph Kaldrymides; I Kostoglou-Athanassiou; A Gkountouvas; E Veniou; N Ziras
Journal:  Endocrine       Date:  2010-01-06       Impact factor: 3.633

3.  Helix pomatia agglutinin binding glycoproteins in thyroid tumors.

Authors:  Rajeev Parameswaran; Gregory Sadler; Susan Brooks
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

4.  The Effect of BRAF V600E Mutation on Lymph Node Involvement in Papillary Thyroid Cancer.

Authors:  Samet Sahin; Gul Daglar; Ebru Menekse; Busranur Cavdarli; Tolga Baglan
Journal:  Turk J Surg       Date:  2020-09-28

5.  The prevalence and prognostic value of BRAF mutation in thyroid cancer.

Authors:  Electron Kebebew; Julie Weng; Juergen Bauer; Gustavo Ranvier; Orlo H Clark; Quan-Yang Duh; Daniel Shibru; Boris Bastian; Ann Griffin
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

6.  Higher EU-TIRADS-Score Correlated with BRAF V600E Positivity in the Early Stage of Papillary Thyroid Carcinoma.

Authors:  Karolina Skubisz; Joanna Januszkiewicz-Caulier; Patrycja Cybula; Elwira Bakuła-Zalewska; Krzysztof Goryca; Agnieszka Paziewska; Filip Ambrożkiewicz; Kosma Woliński; Michał Mikula; Jerzy Ostrowski; Marek Dedecjus
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

7.  New insight into the treatment of advanced differentiated thyroid cancer.

Authors:  Arash Safavi; Aparna Vijayasekaran; Marlon A Guerrero
Journal:  J Thyroid Res       Date:  2012-12-27

8.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  Scott N Pinchot; Rebecca S Sippel; Herbert Chen
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

Review 9.  Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.

Authors:  Franclim Ricardo Ribeiro; Ana Margarida Meireles; Ana Sofia Rocha; Manuel Rodrigues Teixeira
Journal:  BMC Cancer       Date:  2008-12-16       Impact factor: 4.430

10.  NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas.

Authors:  B Górka; J Skubis-Zegadło; M Mikula; K Bardadin; E Paliczka; B Czarnocka
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.